Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus H1N1 vaccine - Seqirus

Drug Profile

Influenza A virus H1N1 vaccine - Seqirus

Alternative Names: A(H1N1) influenza vaccine - Seqirus; A/H1N1-SOIV (swine flu) vaccine - Seqirus; A/H1N1v vaccines - Seqirus; Adjuvanted cell culture-based influenza A H1N1 (2009) monovalent vaccine (Celtura®) - Seqirus; Celtura; Fluvirin A(H1N1) monovalent vaccine - Seqirus; Fluvirin A/H1N1; Focetria; H1N1 pandemic influenza virus vaccine - Seqirus; MF59-eH1N1 - Seqirus; Monovalent A/H1N1 influenza vaccine - Seqirus; Swine flu vaccine - Seqirus; Swine-origin influenza A/H1N1 virus monovalent subunit vaccine - Seqirus

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Seqirus
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 09 Nov 2015 CSL’s influenza vaccine business started operating under the brand name Seqirus
  • 18 Jul 2011 US FDA approves Fluvirin® for the 2011-2012 influenza season in USA
  • 13 Jun 2011 Novartis completes a Phase-III trial in Influenza-A virus H1N1 subtype in Belgium, Germany and Switzerland (NCT00970177)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top